Key result
A high PARIS thrombotic risk score was associated with a significantly increased risk of coronary thrombotic events compared to a low score in Chinese patients after PCI (HR 3.14).
Why the study?
Does the PARIS thrombotic risk score predict coronary thrombotic events in a Chinese population undergoing percutaneous coronary intervention?
Observational (n=9,782)
No
Does the PARIS thrombotic risk score predict coronary thrombotic events in a Chinese population undergoing percutaneous coronary intervention?
Hazard Ratio: 3.14 (95% CI 1.92–5.13)
p-value: p=<0.001
The PARIS thrombotic risk score demonstrates modest prognostic value for predicting 2-year coronary thrombotic events in a real-world Chinese PCI population.
Supports PARIS score for stratification in Chinese post-PCI patients; extends validation but leaves open prospective utility.
BACKGROUND: The patterns of nonadherence to antiplatelet regimen in stented patients (PARIS) thrombotic risk score are a novel score for predicting the risk of coronary thrombotic events (CTEs) after percutaneous coronary intervention (PCI) with drug-eluting stents. However, the prognostic value of this score has not been fully evaluated in non-Euro-American PCI populations. METHODS: We performed a prospective, observational study of 10,724 patients who underwent PCI in Fuwai hospital, China and evaluated the PARIS thrombotic risk score's predictive value of CTEs in the PCI population. The area under the receiver operating characteristic curve (AUROC) was used to assess the predictive value of the PARIS score for CTE. RESULTS: Among 9782 patients without in-hospital events, a total of 95 CTEs occurred during the 2-year follow-up. The PARIS score was significantly higher in patients with CTEs (3.38 ± 2.04) compared with patients without events (2.53 ± 1.70, P < 0.001). According to the risk stratification of the PARIS thrombotic score, the risk of CTEs in the high-risk group was 3.14 times higher than that in the low-risk group (hazard ratio [HR], 3.14; 95% confidence interval [CI], 1.92-5.13; P < 0.001). However, the risk of CTEs in the intermediate-risk and low-risk groups was not significant (HR, 1.39; 95% CI, [0.86-2.24]; P = 0.184). The PARIS score showed prognostic value in evaluating CTEs in the overall population (AUROC, 0.621; 95% CI, 0.561-0.681), the acute coronary syndrome (ACS) population (AUROC, 0.617; 95% CI, 0.534-0.700; P = 0.003), and the non-ACS population (AUROC, 0.647; 95% CI, 0.558-0.736; P = 0.001). CONCLUSIONS: In a real-world Chinese population, the PARIS thrombotic risk score shows a modest prognostic value for CTEs in patients after PCI. This score also has a predictive value for CTEs in the ACS and non-ACS subgroup populations.
No takes yet. Share an insight, caveat, or question.
Li et al. (2018) conducted an observational in Percutaneous Coronary Intervention (n=9,782). High PARIS thrombotic risk score vs. Low PARIS thrombotic risk score was evaluated on Coronary thrombotic events (CTEs) (HR 3.14, 95% CI 1.92-5.13, p=<0.001). A high PARIS thrombotic risk score was associated with a significantly increased risk of coronary thrombotic events compared to a low score in Chinese patients after PCI (HR 3.14).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: